Hence, future work should especially prioritize synergizing nanoparticle‐based PSMA targeting with ADT, PARP inhibition, and immunotherapy to address the unique therapeutic challenges of PCa. The gene discussed is FOLH1; the disease is posterior cortical atrophy.